Treats benign prostatic hyperplasia. ANDA 203192, held by Unichem Laboratories. Alfuzosin Hydrochloride.
As of Nov 22, 2026, ANDA 203192 (Alfuzosin Hydrochloride), held by Unichem Laboratories, was first approved by FDA on Jan 28, 2016, with 2 approved supplements and 0 published complete response letters.
Alfuzosin hydrochloride extended-release tablets, USP, an alpha adrenergic antagonist, are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. Important Limitations of Use: Alfuzosin hydrochloride extended-release tablets, USP are not indicated for treatment of hypertension. Alfuzosin hydrochloride extended-release tablets, USP are not indicated for use in pediatric population. ( 1.1, 8.4, 12.3 )
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 28, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Alfuzosin Hydrochloride10MG · tablet, extended release;oral | Alfuzosin Hydrochloride | Rx |
| Sep 4, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| Dec 7, 2018 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 28, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters